The 2019 conference will take place on the 27th & 28th February 2019 at the Royal College of Physicians, London. Registration will be opening soon. If you’d like to be notified when registration opens send an email to email@example.com .
If you’re interested in sponsorship opportunities for the 2019 conference email Nicole Dixon at firstname.lastname@example.org or call 0191 241 4523.
Certificates of attendance we’re emailed to attendees on the 9th March. If you have not received yours please contact email@example.com
The first joint BSG and Irish Sarcoma Group conference took place in Birmingham on Tuesday 27th & Wednesday 28th February 2018 at The Repertory Theatre, Birmingham. The event included the The National Sarcoma Forum which took place on Tuesday, 27th February along with the BSG evening dinner the same evening.
The programme included the presentation of the results of trials in radiation, medical and surgical Oncology. The meeting was a mixture of interactive discussions chaired by experts, submitted free papers and lectures in addition to poster presentations and break-out meetings on specific topics.
Congratulations to our best oral and poster winners from BSG 2018:
View and download the full conference programme and abstract book below:
PharmaMar are proud to be the main sponsor again of the BSG 2018. The highly regarded Prof Amant from the Netherlands Cancer institute “Antoni Van Leeuwenhoek” will be talking on “The treatment of Uterine Leiomyosarcomas”. Plus Dr Radha Todd the experienced Sarcoma Specialist from the Royal Victoria Infirmary, Newcastle, will present a case study on “The Long term usage of Trabectedin”
For more than fifty years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world.
At TAKEDA ONCOLOGY, we endeavour to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies.